Literature DB >> 15370202

PI3-kinase regulates survival of chronic lymphocytic leukemia B-cells by preventing caspase 8 activation.

Janet M D Plate1.   

Abstract

Studies to investigate signal transduction pathways that support viability and prevent apoptosis of chronic lymphocytic leukemia cells (CLL) were initiated as a result of microarray cDNA analyses which revealed expression of genes whose products regulate cell cycle progression. Immunoblots revealed translation of several genes including caspases, cyclin D1, and the PI3-kinase dependent, survival kinase, Akt. Akt was found to be activated. Inhibition of PI3-kinase with specific inhibitor, LY294002, led to the induction of apoptosis that was caspase 8 dependent, but independent of Akt as LY294002 did not depress a high basal level of Akt activity found in CLL cells. Phosphorylation of Akt was maintained, enzymatic activity undiminished, and phosphorylation of substrates sustained. Caspases, however were activated, PARP cleaved and DNA fragmented. Caspase inhibitors revealed that initiator caspase 8 was required for classic apoptosis when PI3-kinase was inhibited, and specific activity assays demonstrated its early activation. GSK-3beta a kinase regulated via PI3-kinase dependent, down-stream kinases, was responsible for regulating cyclin D1 levels in CLL cells, but neither GSK-3beta nor calpain was responsible for induction of apoptosis, or activation of executioner caspase 3, following LY294002 treatment. PI3-kinase mediated protection against caspase activation in CLL B-cells therefore is not mediated through classic Akt survival pathways. The data further support the hypothesis that signal transducing, membrane associated receptors triggered by extrinsic factors, maintain CLL leukemic B-cell survival in vivo by preventing caspase activation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15370202     DOI: 10.1080/10428190410001683642

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  10 in total

Review 1.  Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.

Authors:  Kumudha Balakrishnan; Varsha Gandhi
Journal:  Expert Opin Investig Drugs       Date:  2012-03-09       Impact factor: 6.206

2.  On CK2 regulation of chronic lymphocytic leukemia cell viability.

Authors:  Leila R Martins; Paulo Lúcio; Milene C Silva; Paula Gameiro; Maria G Silva; João T Barata
Journal:  Mol Cell Biochem       Date:  2011-07-13       Impact factor: 3.396

3.  Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.

Authors:  Matthias Niedermeier; Bryan T Hennessy; Zachary A Knight; Marina Henneberg; Jianhua Hu; Antonina V Kurtova; William G Wierda; Michael J Keating; Kevan M Shokat; Jan A Burger
Journal:  Blood       Date:  2009-03-24       Impact factor: 22.113

4.  Akt inhibitors induce apoptosis in chronic lymphocytic leukemia cells.

Authors:  Mercè de Frias; Daniel Iglesias-Serret; Ana M Cosialls; Llorenç Coll-Mulet; Antonio F Santidrián; Diana M González-Gironès; Esmeralda de la Banda; Gabriel Pons; Joan Gil
Journal:  Haematologica       Date:  2009-10-08       Impact factor: 9.941

5.  Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival.

Authors:  Robert T Woodland; Casey J Fox; Madelyn R Schmidt; Peter S Hammerman; Joseph T Opferman; Stanley J Korsmeyer; David M Hilbert; Craig B Thompson
Journal:  Blood       Date:  2007-10-17       Impact factor: 22.113

Review 6.  Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.

Authors:  Yair Herishanu; Ben-Zion Katz; Andrew Lipsky; Adrian Wiestner
Journal:  Hematol Oncol Clin North Am       Date:  2013-04       Impact factor: 3.722

7.  Rewiring of sIgM-Mediated Intracellular Signaling through the CD180 Toll-like Receptor.

Authors:  Nino Porakishvili; Ketki Vispute; Andrew J Steele; Nadeeka Rajakaruna; Nina Kulikova; Tamar Tsertsvadze; Amit Nathwani; Rajendra N Damle; Edward A Clark; Kanti R Rai; Nicholas Chiorazzi; Peter M Lydyard
Journal:  Mol Med       Date:  2015-01-14       Impact factor: 6.354

8.  The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions.

Authors:  Samantha D Pauls; Sandrine T Lafarge; Ivan Landego; Tingting Zhang; Aaron J Marshall
Journal:  Front Immunol       Date:  2012-08-09       Impact factor: 7.561

9.  Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specific cell-permeable peptide inhibitor.

Authors:  Leila R Martins; Yasser Perera; Paulo Lúcio; Maria G Silva; Silvio E Perea; João T Barata
Journal:  Oncotarget       Date:  2014-01-15

10.  A de novo transcriptome analysis shows that modulation of the JAK-STAT signaling pathway by salmonid alphavirus subtype 3 favors virus replication in macrophage/dendritic-like TO-cells.

Authors:  Cheng Xu; Øystein Evensen; Hetron Mweemba Munang'andu
Journal:  BMC Genomics       Date:  2016-05-23       Impact factor: 3.969

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.